Compare Bristol-Myers Squibb Co (BMY) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.94 (market cap $129.94B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.66. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | EMLC | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $26.59 |
52-Week Low | $42.60 | $24.83 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
EMLC trades at $25.655, up 0.14% with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent dividend distributions, with recent payouts of $0.14 in June 2026. Support and resistance cluster around $26, indicating a key price level. Financial ratios are not provided in the snapshot, limiting fundamental assessment.
Outlook hinges on emerging market debt dynamics and Federal Reserve policy, as noted in recent news. Risks include volatility from macroeconomic shifts and regional instability. The technical setup suggests near-term stability, but fundamental clarity is needed for long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
